Cardiac rehabilitation performance predicts 1-year major adverse cardiovascular events - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35904222/
doi: 10.1002/clc.23890. Online ahead of print. 1 Internal Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. 2 School of Medicine, University of...
Conclusion: Our proposed CR-score accurately identifies patients at high risk for 1-year MACE following the rehabilitation program. Multicenter validation is required.
Share
Conclusions: SVI varies across the US states and is associated with prevalent cardiovascular comorbidities and ASCVD, independent of age, race and ethnicity, sex, employment, income, and health care coverage. SVI may be a useful assessment tool for health policy makers and health systems researchers examining multilevel influences on...
Share
Pleiotropic Benefits of Statins in Cardiovascular Diseases
Source : https://www.thieme-connect.de/products/ejournals/abstract/10.1055/a-1873-1978
Drug Res (Stuttg) DOI: 10.1055/a-1873-1978 1 Department of Pharmacology, Faculty of Pharmacy, Integral University, Lucknow, India 1 Department of Pharmacology, Faculty of Pharmacy, Integral University, Lucknow, India 1...
Relevance: This article examines some of the existing molecular explanations underlying statin pleiotropy and discusses if they have clinical relevance in cardiovascular diseases.
Share
Long-term efficacy and safety of moderate-intensity statin with ezetimibe combination therapy versus high-intensity statin monotherapy in patients with atherosclerotic cardiovascular disease (RACING): a randomised, open-label, non-inferiority trial
Source : https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00916-3/fulltext
Among patients with ASCVD, moderate-intensity statin with ezetimibe combination therapy was non-inferior to high-intensity statin monotherapy for the 3-year composite outcomes with a higher proportion of patients with LDL cholesterol...
Interpretation: Among patients with ASCVD, moderate-intensity statin with ezetimibe combination therapy was non-inferior to high-intensity statin monotherapy for the 3-year composite outcomes with a higher proportion of patients with LDL cholesterol concentrations of less than 70 mg/dL and lower intolerance-related drug discontinuation or dose...
Share
Evolocumab for prevention of microvascular dysfunction in patients undergoing percutaneous coronary intervention: the randomised, open-label EVOCATION trial
Masaharu Ishihara 1, MD, PhD; Masanori Asakura 1 , 2, MD, PhD; Kiyoshi Hibi 3, MD, PhD; Kozo Okada 3, MD, PhD; Wataru Shimizu 4, MD, PhD; Hitoshi Takano 4,...
Conclusion: In summary, empagliflozin activated Wnt/β-catenin to stimulate FUNDC1-dependent mitochondrial quality surveillance, ultimately improving mitochondrial function and cardiac performance during CRS-3. Thus, empagliflozin could be considered for the clinical management of heart function following acute kidney injury.
Conclusions:...
Share